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Due to the shortage of organs, living donor acceptance
criteria are becoming less stringent. An accurate
determination of the glomerular filtration rate (GFR) is critical
in the evaluation of living kidney donors and a value
exceeding 80 ml/min per 1.73 m2 is usually considered
suitable. To improve strategies for kidney donor screening,
an understanding of factors that affect GFR is needed. Here
we studied the relationships between donor GFR measured
by 125I-iothalamate clearances (mGFR) and age, gender, race,
and decade of care in living kidney donors evaluated at the
Cleveland Clinic from 1972 to 2005. We report the normal
reference ranges for 1057 prospective donors (56% female,
11% African American). Females had slightly higher mGFR
than males after adjustment for body surface area, but there
were no differences due to race. The lower limit of normal for
donors (5th percentile) was less than 80 ml/min per 1.73 m2
for females over age 45 and for males over age 40. We found
a significant doubling in the rate of GFR decline in donors
over age 45 as compared to younger donors. The age of the
donors and body mass index increased over time, but their
mGFR, adjusted for body surface area, significantly declined
by 1.49±0.61 ml/min per 1.73 m2 per decade of testing. Our
study shows that age and gender are important factors
determining normal GFR in living kidney donors.
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Living donor kidney transplantation is currently considered
the best treatment for end-stage renal disease (ESRD)
patients.1,2 Owing to the unfortunate combination of a high
incidence of patients with ESRD and a concomitant increased
waiting time for suitable deceased donors, there is increasing
pressure for the acceptance criteria for living kidney donors
to become more liberal and variable.3 Current recommenda-
tions suggest that living kidney donors should have a
glomerular filtration rate (GFR) of at least 80 ml/min per
1.73 m2 regardless of age, gender, or race to proceed with
donation.4–8 Consistent with this approach, the National
Kidney Foundation (NKF) advocates the use of a fixed cutoff
value of estimated GFR (eGFR) to define chronic kidney
disease (CKD).9 In fact, the current Kidney Disease Out-
comes Quality Initiative recommendations allow the diag-
nosis of CKD when a subject demonstrates an eGFR below
60 ml/min per 1.73 m2 independent of underlying clinical
status or other evidence of kidney damage such as
proteinuria. Because of the increasing demand for organs as
well as the constantly changing demographics of the
American population, the suitability of the evaluated kidney
donor, including renal function, has also evolved into less
strict clinical criteria of acceptance.3,4,10 Thus, characterizing
the current reference ranges of GFR will provide extremely
important knowledge to improve classification between
normal kidneys and kidneys with disease.
Unique to the practice of medicine, potential living kidney
donors undergo extensive evaluation with the central goal of
confirming suspected health instead of suspected disease. A
crucial component of the evaluation involves the assessment
of renal function. Most centers perform this critical step
using either eGFR or a timed creatinine clearance, despite
known inaccuracies with these methods.11–14 Other aspects of
the medical evaluation process include ruling out hyperten-
sion, diabetes, and preexistent kidney disease, because
unilateral nephrectomy with any of these conditions may
compromise needed kidney function. As such, kidney donors
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who pass the medical evaluation may be regarded as being
‘healthy’ or ‘normal.’ Indeed, long-term follow up studies
have shown that kidney donors may even live longer15 with
minimal risk of developing ESRD.16 However, the living
donor population is rapidly changing. Data from the Organ
Procurement and Transplantation Network show that the
proportion of living kidney donors who are at least 50 years
old has almost doubled over the past 20 years.17 In fact, some
transplant programs have even begun to allow selected
hypertensive individuals to donate with encouraging short-
term follow-ups.18
The investigation of GFR in ‘health’ has been a subject of
research for the past 70 years.19,20 Most prior studies have not
included African-American (AA) subjects and in several
studies, a complete and thorough evaluation to rule out
occult co-morbidities or disease was not carried out or
sample size was small. On the basis of previous reports, GFR
is known to decline with aging,19,21–23 and may vary by sex
and race.24–26 Thus, the lower limit of normal GFR in subjects
medically cleared to donate a kidney may be expected to vary
depending on these demographic factors. With the changing
characteristics of the general population, there may also be
secular trends in GFR for the potential donor population.
The extensive research database of 125I-iothalamate GFR
studies performed at the Cleveland Clinic over more than 30
years provides a unique opportunity to characterize normal
GFR in Caucasians, but more importantly in AA subjects, a
hitherto understudied population. The main objectives of
our current study are (1) to analyze and characterize
GFR as measured by 125I-iothalamate urinary clearances in
a healthy adult population, including AA subjects, and
compare it with creatinine-based eGFR, (2) to study the
relationships between donor GFR and age, gender, race, and
body size, and (3) to quantify any variation in GFR over time
as a consequence of temporal changes in the population
characteristics.
RESULTS
Population characteristics
Figure 1 shows how the study sample was identified. After
exclusion of international donors (n¼ 51), a total of 1481
subjects were screened for analyses. Of these, 317 subjects
completed the donor evaluation but were deemed not
suitable donor candidates due to medical abnormalities
discovered during the evaluation. The causes for medical
exclusion were: hypertension (n¼ 69, 22%), obesity (body
mass index (BMI) greater than 35) (n¼ 33, 10%), proteinur-
ia, hematuria or abnormal renal anatomy identified by
imaging studies (n¼ 49, 15%), disorders of glucose metabo-
lism or diabetes mellitus (n¼ 20, 6%), bilateral kidney stones
(n¼ 18, 6%), malignancy or high risk for malignancy (n¼ 9,
3%), chronic infections (n¼ 14, 4%), familial or genetic
diseases (n¼ 6, 2%), isolated low GFR (n¼ 43, 14%), and
others (n¼ 56, 18%). Another 150 potential living kidney
donors completed the medical evaluation but did not
donate (mostly because of alternative donors becoming
available, recipients becoming not transplantable, or positive
cross-match). Importantly, no medical abnormalities were
discovered in this subgroup. The other 1014 donors under-
went unilateral donor nephrectomy, either at the Cleveland
Clinic (n¼ 875) or at a different institution (n¼ 139). As
mentioned above, 43 prospective donors passed the medical
evaluation but were not approved for donation because the
transplant committee’s arbitrary opinion was that their
measured GFR (mGFR) was too low. To define reference
ranges in a study sample that was not selected on GFR, they
were included in the final study sample for mGFR (n¼ 1057)
and eGFR (n¼ 545).
The characteristics of all screened subjects are shown in
Table 1. The mean age of the approved donors (n¼ 1014) was
38.5±10.4 years, 56% were women, and 11.1% were AA. The
mean adjusted mGFR was 107.6±16.8 ml/min per 1.73 m2.
Those subjects who were found to have a medical condition
were older (43.9±12.0 years, Pr0.001), had a higher BMI
(28.0±5.0, Po0.001), and had a lower mGFR (98.8 ml/min
per 1.73 m2, Po0.001) (Figure 2) than the approved donors.
The mGFR of those subjects in whom the evaluation was not
completed was similar, suggesting that most of these subjects
would have actually been approved for donation.
AA donors (n¼ 113) were younger than non-AA
(n¼ 901) (36.1±9.1 vs 38.8±10.5 years old, P¼ 0.003),
had a higher BMI (27.6±4.2 vs 26.1±4.2, Pr0.001) and had
a higher serum creatinine level (0.96±0.22 vs 0.90±0.14,
P¼ 0.002). Female donors (n¼ 569) were older than male
donors (n¼ 445) (39.6±10.3 vs 37.2±10.5, Po0.001), less
heavy (25.5±4.4 vs 27.2±3.8, Po0.001), and had a lower
serum creatinine (0.80±0.14 vs 1.04±0.17, Po0.001).
Donors older than 45 years of age (n¼ 284) were heavier
(BMI 26.8±3.9 vs 26.0±4.3, P¼ 0.009) and had lower
creatinine values than younger ones (n¼ 730) (creatinine
0.87±0.20 vs 0.92±0.19, P¼ 0.003).
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Figure 1 | Breakdown of prospective living kidney donors.
Note: Excluded for serum creatinine prior to 1996 (n¼ 512). CCF,
Cleveland Clinic Foundation.
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Relationship between age, gender, and race with mGFR
By univariate analysis, there were statistically significant
differences in adjusted mGFR between women and men
(108.7±17.5 vs 106.1±15.8 ml/min per 1.73 m2, P¼ 0.015)
but not AA compared with non-AA (108.5±14.8 vs
107.4±17.1 ml/min per 1.73 m2, P¼ 0.47). Donors older
than 45 years of age had a lower mGFR than younger ones
(101.5±16.6 vs 109.9±16.4 ml/min per 1.73 m2, respectively,
Po0.001). By multivariate linear regression analysis, donor
gender (women had 3.61 ml/min per 1.73 m2 higher mGFR
than men, Po0.001) and donor age (mGFR declined at a rate
of 3.73 ml/min per 1.73 m2 per decade of life up to the age
of 45 years, Po0.001, and at a rate of 7.53 ml/min per
1.73 m2 thereafter, Po0.001) (Figure 3), but not donor race
(0.35 ml/min per 1.73 m2 in AA vs non-AA, P¼ 0.83) were
found to be factors associated with mGFR.
Secular trends with mGFR
We then studied whether mGFR has changed over three
decades from changes in donor acceptance criteria and
changes in the general population as a whole. The age and
BMI of the accepted donors significantly increased over the
past three decades (3.38 years of age and 0.86 units of BMI
for every 10-year increase in calendar year of testing,
Po0.001 for both), whereas the uncorrected mGFR
remained stable over time (0.14 ml/min for every 10-year
increase in calendar year of testing, P¼ 0.86). Consequently,
the mGFR adjusted for body surface area (BSA) of living
donors has decreased by 1.49±0.61 ml/min per 1.73 m2 per
decade (P¼ 0.015) (Figure 4).
Comparison of mGFR with eGFR
Table 2 shows the lower and upper limits of normal values for
mGFR corrected for BSA and how GFR varies based on
demographic variables. eGFR by the re-expressed Modifica-
tion of Diet in Renal Disease (MDRD) study equation is also
shown. The mGFR is consistently higher than the eGFR in
non-AA subjects. A difference between mGFR and eGFR in
AA subjects was less evident, though it should be noted that
the MDRD equation factors AA with a 21.2% higher eGFR
than in non-AA at the same serum creatinine level. We then
calculated the mean expected mGFR and eGFR for male and
female living donors (with the estimated 5th and 95th
percentile reference range) (Table 3). This analysis was not
stratified based on race, because unlike age and sex, there was
no difference in mean mGFR by race groups. Estimates of
eGFR during 1996–2005 (n¼ 545) by the re-expressed
MDRD equation as stratified by gender and age are also
shown for comparison. Figure 5 shows how the expected
eGFR using data from Table 3 compares to previously
reported eGFR derived from a predominantly Caucasian
European healthy population.27,28
Comparison of a low GFR by classification systems
During the study period, individuals were excluded from
donation by a committee opinion for an isolated low mGFR.
Table 4 compares the number and percentage of potential
donors who would have been excluded from donation with
different classification systems and how these donors would
have differed with respect to GFR and demographics.
Consistent with the underestimation of GFR in kidney
Table 1 | Living kidney donor characteristics
Medically disqualified for donation
Approved donors All Isolated ‘low GFR’ Incomplete donor evaluation
n (%) 1014 (68.4) 317 (21.4) 43 (2.9) 150 (10.1)
Age (years) 38.5±10.4 43.9±12.0* 51.6±10.4* 40.8±10.5*
Age 445 year old, n (%) 284 (28.0) 155 (48.9)* 32 (74.4)* 51 (34.0)
Female gender 569 (56.1) 194 (61.2) 27 (62.8) 88 (58.7)
African American 113 (11.1) 48 (15.1) 4 (9.3) 18 (12.0)
Evaluations prior to 1990 300 (29.6) 84 (26.5) 1 (2.3)* 17 (11.3)*
Body surface area 1.86±0.23 1.88±0.20 1.92±0.23 1.89±0.23
Body mass index (kg/m2) 26.2±4.2 28.0±5.0* 28.4±5.0* 27.5±4.8*
mGFR/BSA (ml/min per 1.73 m2) 107.6±16.8 98.8±22.0* 73.4±4.9* 107.6±17.1
mGFR (ml/min) 115.4±21.8 107.4±26.0* 81.5±11.7* 116.9±20.4
BSA, body surface area; mGFR, measured glomerular filtration rate.
*Po0.05 compared with approved donors.
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donors by the MDRD equation, substantially more donors
would have been excluded by eGFR than by donor committee
(27.1 vs 4.1%, Po0.001). Assuming an mGFR cutoff value of
greater than 80 ml/min per 1.73 m2 to allow donation, from
545 subjects with both mGFR and eGFR, 12 subjects had an
eGFR above that value out of 38 subjects with an mGFR
below that cutoff (false-positive rate of 31.5%), and of 507
subjects with an mGFR above the cutoff, 122 subjects would
have been rejected by eGFR (false-negative rate of 24.1%).
The specificity and sensitivity of eGFR to accept or reject
subjects based on an mGFR value of 80 ml/min per 1.73 m2
was 68.4 and 75.9%, respectively. The donor committee
exclusions were more consistent with exclusion by mGFR
o80 ml/min per 1.73 m2 (kappa¼ 0.73) than age- and sex-
specific thresholds (kappa¼ 0.44–0.45). Persons who would
be excluded from donation based on Cleveland Clinic
age–sex-specific 5th percentile and Mayo Clinic age-specific
5th percentile showed some consistency (kappa¼ 0.75).
Switching from a donor committee or an mGFR o80 ml/
min per 1.73 m2 to age–sex-specific thresholds would lead to
a similar number of overall exclusions, but an overall younger
age and higher GFR among persons who are excluded.
DISCUSSION
Our study contributes to the current literature because of
several novel and clinically important findings: (1) we
provide information for normal reference values of both
measured and eGFR in the single largest cohort of living
kidney donors undergoing strict medical evaluation (who
thus can be characterized as ‘healthy subjects’), (2) we
characterize differences in normal GFR based on age, gender,
and race, and (3) we describe secular trends of donor
demographic and anthropometric changes over a 30-year
period and their impact on kidney function. Importantly,
knowledge of renal function in health has recently been a
matter of intense scrutiny by the NKF and the medical
scientific community.9,29 Therefore, the information derived
from this cohort of living kidney donors is also of significant
relevance to the medical community in general because it
characterizes the normal range of GFR.
Gaining information about kidney function is perhaps one
of the most critical elements in determining the state of
health in prospective kidney donors. Current recommenda-
tions suggest that potential donors with a GFR of 80 ml/min
per 1.73 m2 are acceptable for donation. However, this cutoff
value is weakly supported by medical evidence.4,5 Moreover,
these recommendations do not clearly specify the techniques
to calculate renal function. The majority of transplant centers
rely on creatinine clearances, which overestimates GFR, and
may be allowing donation in subjects with lower than ideal
GFR for age and gender. Also, the NKF advocates a
predefined cutoff value of eGFR for defining ‘health’ vs
‘disease’ irrespective of age and gender (and perhaps race).9
Concerns about this approach have recently been raised
because of the possibility of misclassifying subjects with low
eGFR as ‘diseased’ rather than as ‘at risk’ or simply healthy
for their age and gender.30–34 The observations derived from
this study provide further evidence against recommendations
of using ‘fixed’ GFR cutoff levels irrespective of age, gender,
and race (critical variables in the MDRD equation). In fact, in
this relatively young cohort, women over the age of 50 years
were at risk of being misclassified as having CKD on the
primary basis of an isolated low eGFR. Moreover, assuming a
physiological GFR decline of approximately 8 ml/min per
1.73 m2 per decade after the age of 45 years, one could also
expect that low eGFRs will be common in healthy aging
subjects. Reasoning behind this approach is based on
epidemiologic data that show a decreased eGFR being
associated with increased mortality.35 However, in the setting
of living donation, it is yet unclear whether these former
donors with low normal eGFR values are at risk for a
progressive decline in GFR other than what is expected with
aging. In fact, most data suggest that former donors are at
similar risk for developing ESRD and a higher life expectancy
than the general population, despite having lower post-
donation GFR than controls.15,16,36–39 The information on
donor GFR presented here suggests we should reconsider the
use of ‘fixed’ GFR cutoff values to make clinically important
decisions. From the presented data, it is evident that an
mGFR of 80 ml/min per 1.73 m2 can be higher or lower than
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Figure 3 | Effects of age on renal function. Influence of donor age on the slope of glomerular filtration rate in (a) women and (b) men.
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the estimated lower limits of normal GFR depending on
whether the donor is 25 or 55 years of age. During the donor
selection process, future recommendations should consider
normal GFR reference values based on age and gender prior
to nephrectomy instead of fixed cutoff values, as this
approach may potentially put healthy young subjects at risk
for the development of kidney dysfunction during their
lifetimes, an understudied area in clinical transplantation.
The information on how gender, race, and age relate to
mGFR is another important new observation derived from
this large cohort. Since the early times of study of kidney
function in normal humans, GFR has been normalized to
BSA to account for the effects of body size on absolute GFR,20
an adjustment that more specifically permits a better
comparison between genders and subjects of different
sizes. Most of the published literature suggests that after
adjustment for BSA, women have similar GFR levels to those
of men.22 After correcting for age and race, we found a
statistically higher mGFR in women than men. However, this
difference was no longer present if we studied the entire
cohort (n¼ 1532) that included those subjects who were
found to have a medical condition that prevented them from
donation (data not shown). It was therefore unclear whether
this small difference of less than 3% in a subset of the entire
cohort was a truly biological difference in GFR or it was due
to differences in physiological demand for GFR that is
inadequately modeled by BSA estimated by the Dubois and
Dubois formula published almost a century ago.40 Never-
theless, this difference is unlikely to be clinically relevant.
With respect to AA race, this is the first report to study GFR
in this important sub-population at higher risk for poor renal
outcomes.41 Importantly, in the state of health there is no
difference in normal GFR in AA subjects compared with non-
AA subjects, despite a difference in creatinine levels.
Previous studies have reported on the rate of GFR decline
with aging, another important issue to consider when
defining normality in the context of risk vs disease.
Interestingly, we found that GFR does not display a constant
rate of decline by age, a very important consideration that
theoretically impacts the applicability of a ‘fixed’ age factor
used in current GFR estimation models. We found that the
GFR declines at a rate of approximately 4 ml/min per 1.73 m2
per decade in subjects younger than 45 years of age, similar to
what has been previously reported.22 However, an interesting
finding is that GFR decline seems to accelerate as subjects age
(B8 ml/min per 1.73 m2 per decade after the age 45 years).
Granerus and Aurell42 published similar rates of GFR decline
for subjects younger and older than 50 years of age, and more
recently, Fehrman-Ekholm and Skeppholm37 reported even
faster rates of decline in healthy subjects older than 70 years
of age, suggesting that as human subjects age, GFR declines in
an accelerated manner independent of the presence of
disease. The data derived from this cohort of kidney donors,
in whom an extensive evaluation ruled out significant disease,
suggest that GFR decline is a physiologic process of normal
aging. This observation again suggests that models to screen
for kidney disease or determine normality should account for
age-related physiological variations of organ function. As
shown in Table 4, this approach would exclude about 5% of
donors, similar to the percentage that is excluded by
committee or exclusion by mGFR o80 ml/min per 1.73 m2.
But the excluded donors would be on average younger and
have higher GFRs. It is also interesting to note that the lowest
5th percentile of expected eGFR of the studied population is
similar to the one reported by Wetzels and co-workers27,28 in
a mostly Caucasian community population considered
healthy.
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We finally looked at how the characteristics of the living
donor subjects varied over three decades of GFR testing as
living donation increased in popularity and criteria for
acceptance became less stringent. It is not surprising to see
that older and heavier donors are now being considered for
donation. Although the uncorrected mGFR has remained
stable over time, the mGFR adjusted for BSA has demon-
strated a slight but progressive decrement. This decrease in
mGFR is accounted by the increasing age and BMI of the
living donor population. This is an important epidemiolo-
gical observation of potential future public health consider-
ing that the American population continues to age and
increase in weight.
We recognize several limitations. Kidney donors are a
selected healthy population and therefore some observations
may not be applicable to the general population, which is not
selected on health or disease. This may be a particular
concern in the elderly since only 2/1057 donors were over
the age of 70 years. It is also important to recognize that
some metabolic conditions (for example, hyperuricemia,
dyslipidemia, and so on) may not prevent a subject
from donating but yet may influence kidney function.43
Nevertheless, the fact that kidney donors are selected on
overall health is useful for defining reference ranges.44 Also,
reporting values of eGFR in this study shows the systematic
underestimation of mGFR by the MDRD equation across
the spectrum of age and gender, particularly in non-AA
groups. We also show that there is no difference in the
normal range for mGFR between AA and non-AA race
as others have shown with creatinine clearance.24 It is
also critically important to interpret the presented data on
eGFR with caution as it is not currently advocated by
the NKF to use this method in this clinical setting.
However, comparisons of eGFR with mGFR are used in
this study to demonstrate the limitations of current
approaches to make clinically important decisions. Finally,
to determine the long-term clinical and public health
implications of low GFR under different classification
schemes, further studies assessing outcomes of living donors
by their pre-donation mGFR are needed to assess donor
morbidity and mortality.
In conclusion, careful attention to living donor renal
function evaluation is needed. More importantly, considera-
tion of normal ranges of GFR in health are central to the
decision making process when determining health vs disease,
as well as when selecting living kidney donors, so as to
continue to make this source of organ donation the success
that it has been for the past 50 years.
Table 2 | Observed or actual adjusted GFR by 125I-iothalamate urinary clearances (and eGFR by re-expressed MDRD study
equation) in prospective living kidney donorsa
125I-Iothalamate GFR (eGFR) (ml/min per 1.73 m2)
Groups
Age subgroups
(years)
n mGFR
(n eGFR) 5th percentile 25th percentile Median 75th percentile 95th percentile
All patients Overall 1057 (545) 78 (66) 94 (79) 105 (88) 118 (101) 136 (120)
Non-AA men Overall 411 (189) 76 (68) 94 (81) 104 (89) 116 (102) 133 (117)
18–25 58 (11) 90 (80) 101 (85) 110 (98) 122 (106) 136 (138)
26–35 120 (57) 85 (79) 97 (88) 110 (99) 119 (111) 143 (117)
36–45 123 (55) 82 (71) 96 (84) 103 (93) 115 (105) 129 (121)
46–55 85 (50) 72 (66) 87 (73) 100 (81) 114 (90) 130 (104)
X56 25 (16) 66 (64) 75 (70) 92 (83) 99 (94) 117 (100)
AA men Overall 50 (26) 80 (76) 93 (87) 100 (100) 111 (106) 129 (121)
18–25 9 (1) 109 122 (144) 128
26–35 17 (10) 92 (98) 100 (103) 110 (110)
36–45 16 (7) 93 (91) 97 (103) 106 (105)
46–55 7 (7) 80 (80) 96 (89) 100 (100)
X56 1 (1) 80 (87)
Non-AA women Overall 529 (290) 77 (64) 93 (76) 105 (87) 119 (96) 140 (120)
18–25 46 (13) 91 (77) 103 (102) 122 (103) 129 (117) 148 (146)
26–35 138 (62) 83 (72) 99 (82) 111 (95) 124 (98) 140 (115)
36–45 165 (97) 79 (63) 95 (78) 106 (89) 119 (92) 140 (125)
46–55 137 (94) 80 (67) 90 (76) 97 (86) 111 (88) 132 (120)
X56 43 (24) 68 (53) 76 (65) 91 (74) 98 (85) 122 (98)
AA women Overall 67 (40) 84 (78) 103 (86) 112 (98) 121 (106) 136 (124)
18–25 5 (2) 109 (84) 117 (106) 119 (128)
26–35 25 (11) 106 (99) 115 (101) 123 (118)
36–45 21 (14) 105 (86) 113 (96) 117 (108)
46–55 14 (11) 87 (81) 108 (93) 112 (106)
X56 2 (2) 84 (78) 87 (79) 91 (80)
AA, African American; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; mGFR, measured glomerular filtration rate.
a5th and 95th percentiles were not calculated for subgroups with fewer than 20 subjects.
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MATERIALS AND METHODS
This study was approved by the Institutional Review Board at the
Cleveland Clinic. A historical chart review was performed on all
potential living kidney donors 18 years and older who underwent
125I-sodium iothalamate urinary clearance determinations as part of
the donor evaluation process from January 1974 to December 2005.
All data were retrieved from electronic or paper medical records.
The list of evaluated donors was initially obtained from the Renal
Transplant Program at the Cleveland Clinic, and then cross-checked
with the Renal Function Laboratory registry for accuracy. After a
telephone questionnaire to screen for known medical conditions
Table 3 | ‘Expected’ adjusted GFR by 125I-iothalamate urinary
clearances (and re-expressed MDRD equation) in prospective
living kidney donors derived from the actual or observed
GFR values presented in Table 2a
125I-Iothalamate GFR (re-expressed MDRD study equation)
(ml/min per 1.73 m2)
Age
(years)
Expected 5th
percentile
Mean expected
value
Expected 95th
percentile
Women
20 89 (76) 116 (102) 144 (128)
25 87 (73) 114 (99) 142 (125)
30 85 (70) 113 (96) 140 (122)
35 83 (67) 111 (93) 138 (119)
40 81 (64) 109 (90) 136 (116)
45 79 (61) 107 (87) 134 (113)
50 74 (58) 101 (84) 129 (110)
55 69 (55) 96 (81) 124 (107)
60 64 (52) 91 (78) 119 (104)
Men
20 86 (79) 113 (105) 141 (131)
25 84 (76) 111 (102) 139 (127)
30 82 (73) 109 (99) 137 (124)
35 80 (70) 107 (96) 135 (121)
40 78 (67) 105 (93) 133 (118)
45 76 (64) 103 (90) 131 (115)
50 71 (61) 98 (86) 126 (112)
55 66 (57) 93 (83) 121 (109)
60 60 (54) 88 (80) 116 (106)
GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.
aFor mGFR, all living kidney donors (n=1057), for MDRD all living kidney donors from
1996 to 2005 with measured serum creatinine (n=545).
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Figure 5 | Comparison of estimated GFR in two different
cohorts. Mean, 5th, and 95th percentiles for expected eGFR by
the re-expressed MDRD equation in living kidney donors (black
lines) and eGFR by the re-expressed MDRD equation in subjects
participating in the Nijmegen study28 (gray lines) among different
age groups for (a) men and (b) women.
Table 4 | Comparison of persons who would be excluded for low mGFR among otherwise healthy kidney donors as determined
by different classification systems
What actually
happened What could have happened instead
Characteristics
Excluded by
committee
mGFR
o80 ml/min
per 1.73 m2
a
eGFR
o80 ml/min
per 1.73 m2
a
Mayo Clinic
age-specific
mGFR 5th percentile22
Cleveland Clinic
age–sex-specific
mGFR 5th percenile
n (%) 43 (4.1) 67 (6.3) 148 (27.1) 67 (6.3) 45 (4.2)b
Kappa (agreement) Reference 0.73 0.16 0.44 0.41
mGFR, mean±s.d., n 73.4±4.9, 43 73.2±4.6, 67 94.1±15.4, 148 76.1±7.3, 67 75.4±6.5, 45
eGFR, mean±s.d., n 71.4±10.5, 28 72.5±11.4, 38 71.9±6.6, 148 77.4±15.6, 35 77.4±12.2, 20
Age (years), mean±s.d., n 51.6±10.4, 43 49±11, 67 46.1±9.1, 148 40.2±11.6, 67 38.7±9.6, 45
Men (%) 37.2 43.3 28.4 47.7 33.0
African Americans (%) 9 5.9 4.05 10.4 8.9
aFor mGFR, all living kidney donors (n=1057); for MDRD, all living kidney donors from 1996 to 2005 with measured serum creatinine (n=545).
bNote: For the Cleveland Clinic cutoff points we are using Table 3, which splits individuals out only by age and sex.
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that would disqualify prospective donors up-front, all donors were
invited to visit the Cleveland Clinic for a full medical evaluation.
Donor’s age was not generally used as a criterion to disqualify a
prospective donor, though the extent to which the perception of
health influences that older individuals undergo evaluations as
potential donors is unknown. The race of the subjects was self-
reported. Renal function as measured by 125I-iothalamate GFR
during this initial visit was carried out in all subjects. The donor
evaluation consisted of a full history and physical examination
independently performed by a clinician as well as a surgeon,
followed by an extensive laboratory testing (complete metabolic
profile, blood cell count, lipid panel, glucose tolerance test, viral
serologies, urine analysis and culture, and 24-hour urine collection
for proteinuria), imaging of the urinary tract, chest X-ray, and
electrocardiogram.
Details of 125I-sodium iothalamate GFR determination at the
Cleveland Clinic have been previously described.45 Patients received
a water load before the test. 125I-sodium iothalamate (25 mCu; Glofil;
Questor Pharmaceuticals, Union City, CA, USA) was injected
subcutaneously without epinephrine. Baseline urine and blood
samples were obtained. A voluntary-voided urine sample was
discarded, followed by two timed clearance urine collections. Blood
samples were drawn before and after each urine collection. Isotope
activity was determined by gamma counting of 0.5 ml of plasma or
urine on a Packard Minaxi 5000 series counter (Perkin Elmer Life
Sciences, Downers Grove, IL). The counts in each period were the
average of the samples for each clearance period. The mean mGFR
was calculated from two consecutive clearance values, and the results
were standardized to BSA (1.73 m2) using the Dubois and Dubois
formula.40
GFR was also estimated using the recently re-expressed
MDRD equation after standardizing the serum creatinine
values measured at the Cleveland Clinic traceable to the National
Institute of Standards and Technology sample with the following
formula: Cleveland Clinic standardized serum creatinine¼
0.906 (0.099þ 0.981Cleveland Clinic serum creatinine).46 We
limit the analysis of eGFRs to all the living donors studied after
1996, where serum creatinine calibration bias was determined and
corrected.11 All serum creatinine measurements were performed on
the same day of the GFR measurement.
Statistical analysis
We compared continuous and categorical variables between approved
donors and each of the other two donor categories (‘incomplete
evaluation’ and ‘medically disqualified’ groups) using t-tests and w2
tests, respectively. Among approved donors, we compared AA vs non-
AA, men vs women, and subjects older than 45 years of age vs
younger subjects using t-tests for continuous variables and w2 tests for
categorical variables. We used linear regression to assess the
relationship between age, gender, and race with mGFR as well as
the relationship between time period of testing with mGFR, BMI, and
age. We also used linear regression to obtain predicted estimates and
90% prediction intervals for adjusted mGFR and eGFR at different
levels of age and gender. Assuming that the criteria for living donors
remain the same, we would expect future observations of mGFR from
living donors to have 90% probability of falling within the presented
prediction intervals (that is, the lowest and the highest estimated 5th
percentiles). Observed percentiles (5, 25, 50, 75, and 95) of donor
mGFR and eGFR stratified by gender, race, and age groups using data
from 1996 to 2005 are also reported. The kappa methodology was
used to compare various approaches to donor exclusion solely based
on mGFR, including the cutoffs used by the Mayo Clinic as an
external validation sample.47 A kappa of 1 implies complete
agreement, whereas a kappa of 0 implies agreement no greater than
expected by chance.
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